EGFR and non-small cell lung carcinoma: The third‐generation EGFR TKI osimertinib is demonstrated to be superior to the first‐ and second‐generation EGFR TKIs and used in EGFR T790M mutation‐positive NSCLC and first‐line treatment and adjuvant therapy for NSCLC with EGFR exon 19 deletion or exon 21 (L858R) mutations.124